Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases

Inflammatory Bowel Diseases

Volumn 21, Issue 12, 2015, Pages 2787-2796

  Li, Zhe ^a   Vermeire, Séverine ^a   Bullens, Dominique ^a   Ferrante, Marc ^a   Van Steen, Kristel ^a,b   Noman, Maja ^a   Bossuyt, Xavier ^a   Rutgeerts, Paul ^a   Ceuppens, Jan L ^a   Van Assche, Gert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

anti TNF therapy; B cell subsets; CD40; inflammatory bowel diseases (IBD)

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CD19 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD5 ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; INFLIXIMAB; MESALAZINE; STEROID; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ADULT; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CROHN DISEASE; DRUG BLOOD LEVEL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPREGULATION; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; CYTOLOGY; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES;

ADULT; ANTIGENS, CD19; ANTIGENS, CD40; ANTIGENS, CD5; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84948165647     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000554     Document Type: Article

References (39)

1. Mizoguchi E, Mizoguchi A, Preffer FI, et al. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol. 2000;12:597-605.
2. Croft M, Joseph SB, Miner KT. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells. J Immunol. 1997;159:3257-3265.
3. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med. 1992;175: 131-138.
4. Shah S, Qiao L. Resting B cells expand a CD4+CD25+Foxp3+ Treg population via TGF-beta3. Eur J Immunol. 2008;38:2488-2498.
5. Yang ZZ, Novak AJ, Ziesmer SC, et al. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood. 2007;110:2537-2544.
6. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006; 176:705-710.
7. Tangye SG, Good KL. Human IgM+CD27+ B cells: memory B cells or "memory B" cells? J Immunol. 2007;179:13-19.
8. Bjorck P, Axelsson B, Paulie S. Expression of CD40 and CD43 during activation of human B lymphocytes. Scand J Immunol. 1991;33: 211-218.
9. Chong Y, Ikematsu H, Yamaji K, et al. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol. 2005;17:383-390.
10. Wehr C, Eibel H, Masilamani M, et al. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol. 2004;113: 161-171.
11. Souto-Carneiro MM, Mahadevan V, Takada K, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther. 2009;11:R84.
12. Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med. 1959;110:657-674.
13. Eggena M, Cohavy O, Parseghian MH, et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. JAutoimmun. 2000;14:83-97.
14. Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210.
15. Sattler S, Ling GS, Xu D, et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun. 2014;50:107-122.
16. Neil GA, Summers RW, Cheyne BA, et al. CD5+ B cells are decreased in peripheral blood of patients with Crohn's disease. Dig Dis Sci. 1992;37: 1390-1395.
17. Di Sabatino A, Carsetti R, Rosado MM, et al. Immunoglobulin M memory B cell decrease in inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2004;8:199-203.
18. Yacyshyn BR, Pilarski LM. Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease. Gut. 1993;34:1698-1704.
19. Yacyshyn BR, Meddings JB. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology. 1995;108:132-137.
20. Noronha AM, Liang Y, Hetzel JT, et al. Hyperactivated B cells in human inflammatory bowel disease. JLeukoc Biol. 2009;86:1007-1016.
21. Ferkolj I, Ihan A, Markovic S. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease. Hepatogastroenterology. 2005; 52:1128-1133.
22. Lichtenstein GR. Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment. Curr Opin Gastroenterol. 2000;16:83-88.
23. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest. 1990;86:1255-1260.
24. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res. 2007;149:173-186.
25. van Deventer SJ. Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis. 1999;58(suppl 1):I114-I120.
26. Karampetsou MP, Andonopoulos AP, Liossis SN. Treatment with TNFal-pha blockers induces phenotypical and functional aberrations in peripheral B cells. Clin Immunol. 2011;140:8-17.
27. Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72:1037-1043.
28. Di Sabatino A, Rosado MM, Cazzola P, et al. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. In-flamm Bowel Dis. 2008;14:591-596.
29. Li Z, Arijs I, De Hertogh G, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis. 2010;16:1299-1310.
30. Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152-172.
31. Fu L, Lin-Lee YC, Pham LV, et al. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006;107:4540-4548.
32. Pham LV, Tamayo AT, Yoshimura LC, et al. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood. 2005;106:3940-3947.
33. Liu Z, Colpaert S, D'Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol. 1999;163:4049-4057.
34. Mishima Y, Ishihara S, Amano Y, et al. Alterations of peripheral blood CD5+ B cells in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:172-179.
35. Pers JO, Jamin C, Predine-Hug F, et al. The role of CD5-expressing B cells in health and disease (review). Int J Mol Med. 1999;3:239-245.
36. Bohm I. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed Pharmacother. 2004;58:338-343.
37. van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131:1204-1212.
38. Lee JH, Noh J, Noh G, et al. IL-10 is predominantly produced by CD19 (low)CD5(+) regulatory B cell subpopulation: characterisation of CD19 (high) and CD19(low) subpopulations of CD5(+) B cells. Yonsei Med J. 2011;52:851-855.
39. Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2002;46:2160-2171.